EA201791872A1 - Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение - Google Patents
Полициклические карбамоилпиридоновые соединения и их фармацевтическое применениеInfo
- Publication number
- EA201791872A1 EA201791872A1 EA201791872A EA201791872A EA201791872A1 EA 201791872 A1 EA201791872 A1 EA 201791872A1 EA 201791872 A EA201791872 A EA 201791872A EA 201791872 A EA201791872 A EA 201791872A EA 201791872 A1 EA201791872 A1 EA 201791872A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compounds
- carbamoilpyridone
- polycyclic
- pharmaceutical applications
- disclosed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
Abstract
Раскрыты соединения для применения в лечении инфекции вируса иммунодефицита человека (ВИЧ). Указанные соединения имеют следующую формулу (Ia):включая их стереоизомеры и фармацевтически приемлемые соли, где A, A', Rи Rимеют значения, определенные в настоящем описании. Также раскрыты способы, связанные с получением и применением таких соединений, а также фармацевтические композиции, содержащие такие соединения.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562142338P | 2015-04-02 | 2015-04-02 | |
PCT/US2016/025740 WO2016161382A1 (en) | 2015-04-02 | 2016-04-01 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201791872A1 true EA201791872A1 (ru) | 2018-04-30 |
Family
ID=55754453
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201791872A EA201791872A1 (ru) | 2015-04-02 | 2016-04-01 | Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение |
Country Status (20)
Country | Link |
---|---|
US (1) | US9630978B2 (ru) |
EP (3) | EP3466490B1 (ru) |
JP (2) | JP6402259B2 (ru) |
KR (2) | KR101982431B1 (ru) |
CN (2) | CN110790773A (ru) |
AU (3) | AU2016244035B2 (ru) |
BR (1) | BR112017020837A2 (ru) |
CA (1) | CA2980362C (ru) |
EA (1) | EA201791872A1 (ru) |
ES (2) | ES2837383T3 (ru) |
HK (2) | HK1248688A1 (ru) |
IL (1) | IL254552A0 (ru) |
MX (1) | MX2017012393A (ru) |
NZ (1) | NZ735575A (ru) |
PL (1) | PL3277691T3 (ru) |
PT (2) | PT3466490T (ru) |
SG (1) | SG11201707905WA (ru) |
SI (2) | SI3466490T1 (ru) |
TR (1) | TR201905009T4 (ru) |
WO (1) | WO2016161382A1 (ru) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2822954T1 (sl) | 2012-12-21 | 2016-07-29 | Gilead Sciences, Inc. | Policiklične karbamoilpiridonske spojine in njihova farmacevtska uporaba |
TWI738321B (zh) * | 2014-12-23 | 2021-09-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
HRP20211456T1 (hr) | 2014-12-26 | 2021-12-24 | Emory University | Protuvirusni derivati n4-hidroksicitidina |
CA2980362C (en) * | 2015-04-02 | 2020-02-25 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
US11331331B2 (en) | 2017-12-07 | 2022-05-17 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
CN110526930B (zh) * | 2018-05-23 | 2022-06-03 | 莫云芬 | 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用 |
WO2019230857A1 (ja) | 2018-05-31 | 2019-12-05 | 塩野義製薬株式会社 | 多環性ピリドン誘導体 |
CN117327072A (zh) | 2018-05-31 | 2024-01-02 | 盐野义制药株式会社 | 多环氨基甲酰基吡啶酮衍生物 |
US11084832B2 (en) * | 2019-03-22 | 2021-08-10 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
RU2717101C1 (ru) * | 2019-06-03 | 2020-03-18 | Андрей Александрович Иващенко | Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения |
TW202120510A (zh) * | 2019-11-13 | 2021-06-01 | 大陸商上海拓界生物醫藥科技有限公司 | 新型四環雜環化合物及其藥物用途 |
US20230059640A1 (en) | 2019-11-28 | 2023-02-23 | Shionogi & Co., Ltd. | Prophylactic and therapeutic pharmaceutical agent for hiv infectious diseases characterized by comprising combination of integrase inhibitor and anti-hiv agent |
CN115151545A (zh) | 2020-02-24 | 2022-10-04 | 吉利德科学公司 | 用于治疗hiv感染的四环化合物 |
AU2021351491A1 (en) * | 2020-09-30 | 2023-05-04 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
TW202227445A (zh) * | 2020-10-30 | 2022-07-16 | 大陸商上海拓界生物醫藥科技有限公司 | 抑制基因缺陷的hiv病毒的用途 |
LT4196479T (lt) | 2021-01-19 | 2023-12-11 | Gilead Sciences, Inc. | Pakeistieji piridotriazino junginiai ir jų panaudojimo būdai |
Family Cites Families (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5914331A (en) | 1990-02-01 | 1999-06-22 | Emory University | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
US5204466A (en) | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
US6703396B1 (en) | 1990-02-01 | 2004-03-09 | Emory University | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
US5935946A (en) | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
GB2345058A (en) | 1998-12-01 | 2000-06-28 | Cerebrus Pharm Ltd | Hydroxypyridone compounds useful in the treatment of oxidative damage to the central nervous system |
HUP0201472A3 (en) | 1998-12-25 | 2006-03-28 | Shionogi & Co | Aromatic heterocycle compounds having hiv integrase inhibiting activities |
US20040039060A1 (en) | 2000-06-14 | 2004-02-26 | Ryuichi Kiyama | Inhibitor for enzyme having two divalent metal ions as active centers |
CN101513402B (zh) | 2001-08-10 | 2012-03-21 | 盐野义制药株式会社 | 抗病毒药 |
NZ532018A (en) | 2001-10-03 | 2004-12-24 | Ucb S | Pyrrolidinone derivatives |
ES2258668T3 (es) | 2001-10-26 | 2006-09-01 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Hidroxipirimidina carboxamidas n-sustituidas inhibidoras de hiv integrasa. |
WO2004004657A2 (en) | 2002-07-09 | 2004-01-15 | Bristol-Myers Squibb Company | Hiv integrase inhibitors |
CA2498111A1 (en) | 2002-09-11 | 2004-03-25 | Merck & Co., Inc. | Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors |
ATE443048T1 (de) | 2002-11-20 | 2009-10-15 | Japan Tobacco Inc | 4-oxochinolinverbindungen und deren verwendung als hiv-integrase-inhibitoren |
NZ540728A (en) | 2003-01-14 | 2008-08-29 | Gilead Sciences Inc | Compositions and methods for combination antiviral therapy |
WO2004096286A2 (en) | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Antiviral phosphonate analogs |
TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
TW200528440A (en) | 2003-10-31 | 2005-09-01 | Fujisawa Pharmaceutical Co | 2-cyanopyrrolidinecarboxamide compound |
JP2007519735A (ja) | 2004-01-30 | 2007-07-19 | メルク エンド カムパニー インコーポレーテッド | Hivインテグラーゼ阻害剤として有用であるn−ベンジル−3,4−ジヒドロキシピリジン−2−カルボキサミド及びn−ベンジル−2,3−ジヒドロキシピリジン−4−カルボキサミド化合物 |
AU2005220767A1 (en) | 2004-03-09 | 2005-09-22 | Merck & Co., Inc. | HIV integrase inhibitors |
WO2005110415A1 (en) | 2004-05-07 | 2005-11-24 | Merck & Co., Inc. | Hiv integrase inhibitors |
US7273859B2 (en) | 2004-05-12 | 2007-09-25 | Bristol-Myers Squibb Company | HIV integrase inhibitors: cyclic pyrimidinone compounds |
MY134672A (en) | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
US7531554B2 (en) | 2004-05-20 | 2009-05-12 | Japan Tobacco Inc. | 4-oxoquinoline compound and use thereof as HIV integrase inhibitor |
EP2332538A1 (en) | 2004-05-21 | 2011-06-15 | Japan Tobacco, Inc. | Combinations comprising a 4-isoquinolone derivative and anti-HIV agents |
DK2258376T3 (en) | 2004-07-27 | 2019-04-15 | Gilead Sciences Inc | Phosphonate analogues of HIV inhibitor compounds |
WO2006030807A1 (ja) | 2004-09-15 | 2006-03-23 | Shionogi & Co., Ltd. | Hivインテグラーゼ阻害活性を有するカルバモイルピリドン誘導体 |
CA2634499A1 (en) | 2004-12-23 | 2006-06-29 | Virochem Pharma Inc. | Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase |
EP1852434B1 (en) | 2005-02-21 | 2011-07-13 | Shionogi Co., Ltd. | Bicyclic carbamoylpyridone derivative having hiv integrase inhibiting activity |
CN101212903B (zh) * | 2005-04-28 | 2013-07-24 | 史密丝克莱恩比彻姆公司 | 具有hiv整合酶抑制活性的多环氨基甲酰基吡啶酮衍生物 |
ES2667868T5 (es) | 2005-04-28 | 2023-06-01 | Viiv Healthcare Co | Derivado de carbamoilpiridona policíclico que tiene actividad inhibidora de la integrasa del VIH |
AR057023A1 (es) | 2005-05-16 | 2007-11-14 | Gilead Sciences Inc | Compuestos heterociclicos con propiedades inhibidoras de hiv-integrasa |
CA2616314A1 (en) | 2005-07-27 | 2007-02-01 | Gilead Sciences, Inc. | Antiviral phosphonate conjugates for inhibition of hiv |
ES2569357T3 (es) | 2005-10-27 | 2016-05-10 | Shionogi & Co., Ltd. | Derivado de carbamoilpiridona policíclico que tiene actividad inhibidora sobre integrasa de HIV |
JP4676536B2 (ja) | 2005-12-30 | 2011-04-27 | ギリアド サイエンシズ, インコーポレイテッド | Hivインテグラーゼ阻害剤の薬物動態の改善方法 |
EP2452682A1 (en) | 2006-02-01 | 2012-05-16 | Japan Tobacco, Inc. | Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection |
US8420821B2 (en) | 2006-03-06 | 2013-04-16 | Japan Tobacco Inc. | Process for production of 4-oxoquinoline compound |
US8383819B2 (en) | 2006-03-06 | 2013-02-26 | Japan Tobacco Inc. | Method for producing 4-oxoquinoline compound |
US7893055B2 (en) | 2006-06-28 | 2011-02-22 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
JP2009543865A (ja) | 2006-07-19 | 2009-12-10 | ユニバーシティ オブ ジョージア リサーチ ファウンデーション, インコーポレーテッド | ピリジノンジケト酸:併用療法におけるhiv複製の阻害剤 |
ES2536923T3 (es) | 2006-09-12 | 2015-05-29 | Gilead Sciences, Inc. | Proceso e intermedios para preparar inhibidores de la integrasa del VIH |
EP2084160A1 (en) | 2006-10-18 | 2009-08-05 | Merck & Co., Inc. | Hiv integrase inhibitors |
LT3150586T (lt) | 2007-02-23 | 2020-03-10 | Gilead Sciences, Inc. | Terapinių agentų farmakokinetinių savybių moduliatoriai |
US20080280945A1 (en) | 2007-05-09 | 2008-11-13 | Sachin Lohani | Crystalline forms of an HIV integrase inhibitor |
SG182229A1 (en) | 2007-06-29 | 2012-07-30 | Gilead Sciences Inc | Therapeutic compositions and the use thereof |
JP5547067B2 (ja) | 2007-06-29 | 2014-07-09 | ギリアード サイエンシーズ, インコーポレイテッド | 治療組成物およびその使用 |
AR068403A1 (es) | 2007-09-11 | 2009-11-18 | Gilead Sciences Inc | Proceso e intermediarios para la preparacion de inhibidores de integrasa |
CN101918365B (zh) | 2007-11-16 | 2013-10-09 | 吉联亚科学股份有限公司 | 人类免疫缺陷病毒复制的抑制剂 |
US8129398B2 (en) | 2008-03-19 | 2012-03-06 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
WO2010011813A1 (en) | 2008-07-23 | 2010-01-28 | Alkermes, Inc. | Complex of trospium and pharmaceutical compositions thereof |
PT2320908E (pt) | 2008-07-25 | 2014-03-06 | Shionogi & Co | Pró-fármacos de dolutegravir |
WO2010011819A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
WO2010011815A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
EP2320909B8 (en) | 2008-07-25 | 2016-03-30 | VIIV Healthcare Company | Chemical compounds |
EP2330902B1 (en) | 2008-07-25 | 2012-11-14 | GlaxoSmithKline LLC | Chemical compounds |
WO2010011818A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
BRPI0923217A2 (pt) | 2008-12-11 | 2017-05-23 | Glaxosmithkline Llc | processos para a preparação de um composto de piridona, e para a preparação de uma forma cristalina, composto, sal ou um hidrato deste, forma cristalina de um sal de sódio ou um hidrato deste, e, composição farmacêutica. |
TWI518084B (zh) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
EA202190473A3 (ru) | 2010-01-27 | 2021-12-31 | Вайв Хелткер Компани | Противовирусная терапия |
NZ601847A (en) | 2010-02-26 | 2014-03-28 | Japan Tobacco Inc | 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv integrase inhibitor |
TWI582097B (zh) | 2010-03-23 | 2017-05-11 | Viiv醫療保健公司 | 製備胺甲醯吡啶酮衍生物及中間體之方法 |
WO2011139637A1 (en) | 2010-05-03 | 2011-11-10 | Philadelphia Health & Education Corporation | Small-molecule modulators of hiv-1 capsid stability and methods thereof |
WO2012003498A1 (en) | 2010-07-02 | 2012-01-05 | Gilead Sciences, Inc. | 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds |
ES2634490T3 (es) | 2010-07-02 | 2017-09-28 | Gilead Sciences, Inc. | Derivados de ácido napht-2-ylacetico para tratar el sida |
ES2710609T3 (es) | 2010-08-05 | 2019-04-26 | Shionogi & Co | Procedimiento de preparación de un compuesto que tiene actividad inhibidora de la integrasa del HIV |
AU2011307087B2 (en) | 2010-09-24 | 2016-11-10 | Shionogi & Co., Ltd. | Substituted polycyclic carbamoyl pyridone derivative prodrug |
PE20141066A1 (es) | 2011-04-21 | 2014-09-05 | Gilead Sciences Inc | Compuestos de benzotiazol |
WO2012151361A1 (en) | 2011-05-03 | 2012-11-08 | Concert Pharmaceuticals Inc. | Carbamoylpyridone derivatives |
WO2012151567A1 (en) | 2011-05-05 | 2012-11-08 | St. Jude Children's Research Hospital | Pyrimidinone compounds and methods for preventing and treating influenza |
JP6205354B2 (ja) | 2011-07-06 | 2017-09-27 | ギリアード サイエンシーズ, インコーポレイテッド | Hivの処置のための化合物 |
CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
PL2742051T3 (pl) | 2011-09-14 | 2017-06-30 | Mapi Pharma Limited | Amorficzna postać soli sodowej dolutegrawiru |
BR112014008896A2 (pt) | 2011-10-12 | 2017-04-18 | Shionogi & Co | derivado de piridona policíclico tendo atividade inibidora de integrase |
US9399645B2 (en) | 2011-12-20 | 2016-07-26 | Boehringer Ingelheim International Gmbh | Inhibitors of HIV replication |
ES2571479T3 (es) | 2012-04-20 | 2016-05-25 | Gilead Sciences Inc | Derivados del ácido benzotiazol-6-il acético y su uso para tratar una infección por VIH |
WO2014008636A1 (en) | 2012-07-11 | 2014-01-16 | Merck Sharp & Dohme Corp. | Macrocyclic compounds as hiv integrase inhibitors |
US20150166520A1 (en) | 2012-07-20 | 2015-06-18 | Merck Sharp & Dohme Corp. | Amido-substituted pyrimidinone derivatives useful for the treatment of hiv infection |
EP2877469A4 (en) | 2012-07-25 | 2016-04-06 | Merck Sharp & Dohme | SUBSTITUTED NAPHTHYRIDINEDIONE DERIVATIVES AS INHIBITORS OF HIV INTEGRASE |
EA026089B1 (ru) | 2012-08-03 | 2017-02-28 | Джилид Сайэнс, Инк. | Способ и промежуточные соединения для получения ингибиторов интегразы |
CN104902905A (zh) | 2012-12-14 | 2015-09-09 | 葛兰素史克有限责任公司 | 药物组合物 |
WO2014099586A1 (en) * | 2012-12-17 | 2014-06-26 | Merck Sharp & Dohme Corp. | 4-pyridinonetriazine derivatives as hiv integrase inhibitors |
SI2822954T1 (sl) * | 2012-12-21 | 2016-07-29 | Gilead Sciences, Inc. | Policiklične karbamoilpiridonske spojine in njihova farmacevtska uporaba |
US20140221355A1 (en) | 2012-12-21 | 2014-08-07 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
US20160000721A1 (en) | 2012-12-21 | 2016-01-07 | Merck Sharp & Dohme Corp. | Gastro-retentive formulations |
SG11201504982PA (en) | 2012-12-27 | 2015-07-30 | Japan Tobacco Inc | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND MEDICINAL USE THEREOF AS HIV INTEGRASE INHIBITOR |
US9951079B2 (en) * | 2013-06-13 | 2018-04-24 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as HIV integrase inhibitors |
NO2865735T3 (ru) * | 2013-07-12 | 2018-07-21 | ||
EP3252058B1 (en) * | 2013-07-12 | 2021-01-20 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections |
WO2015039348A1 (en) | 2013-09-23 | 2015-03-26 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors |
EP3049081B1 (en) | 2013-09-27 | 2019-11-27 | Merck Sharp & Dohme Corp. | Substituted quinolizine derivatives useful as hiv integrase inhibitors |
WO2015089847A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Spirocyclic heterocycle compounds useful as hiv integrase inhibitors |
TWI738321B (zh) * | 2014-12-23 | 2021-09-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
CA2980362C (en) * | 2015-04-02 | 2020-02-25 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
-
2016
- 2016-04-01 CA CA2980362A patent/CA2980362C/en active Active
- 2016-04-01 EP EP18207888.1A patent/EP3466490B1/en active Active
- 2016-04-01 NZ NZ735575A patent/NZ735575A/en not_active IP Right Cessation
- 2016-04-01 TR TR2019/05009T patent/TR201905009T4/tr unknown
- 2016-04-01 EP EP16716776.6A patent/EP3277691B1/en active Active
- 2016-04-01 PL PL16716776T patent/PL3277691T3/pl unknown
- 2016-04-01 EP EP20167360.5A patent/EP3736274A1/en not_active Withdrawn
- 2016-04-01 SI SI201630966T patent/SI3466490T1/sl unknown
- 2016-04-01 CN CN201911067354.7A patent/CN110790773A/zh active Pending
- 2016-04-01 ES ES18207888T patent/ES2837383T3/es active Active
- 2016-04-01 MX MX2017012393A patent/MX2017012393A/es unknown
- 2016-04-01 KR KR1020177031329A patent/KR101982431B1/ko active IP Right Grant
- 2016-04-01 KR KR1020197014269A patent/KR20190057158A/ko active Application Filing
- 2016-04-01 EA EA201791872A patent/EA201791872A1/ru unknown
- 2016-04-01 SG SG11201707905WA patent/SG11201707905WA/en unknown
- 2016-04-01 PT PT182078881T patent/PT3466490T/pt unknown
- 2016-04-01 WO PCT/US2016/025740 patent/WO2016161382A1/en active Application Filing
- 2016-04-01 PT PT16716776T patent/PT3277691T/pt unknown
- 2016-04-01 BR BR112017020837-7A patent/BR112017020837A2/pt not_active IP Right Cessation
- 2016-04-01 CN CN201680025671.0A patent/CN107531727B/zh active Active
- 2016-04-01 JP JP2017549768A patent/JP6402259B2/ja active Active
- 2016-04-01 ES ES16716776T patent/ES2718410T3/es active Active
- 2016-04-01 SI SI201630216T patent/SI3277691T1/sl unknown
- 2016-04-01 US US15/089,342 patent/US9630978B2/en active Active
- 2016-04-01 AU AU2016244035A patent/AU2016244035B2/en active Active
-
2017
- 2017-09-18 IL IL254552A patent/IL254552A0/en unknown
-
2018
- 2018-06-27 HK HK18108247.4A patent/HK1248688A1/zh unknown
- 2018-07-09 HK HK18108873.5A patent/HK1249103B/zh unknown
- 2018-09-10 JP JP2018168811A patent/JP6745308B2/ja active Active
- 2018-09-27 AU AU2018236826A patent/AU2018236826B2/en active Active
-
2019
- 2019-12-17 AU AU2019283812A patent/AU2019283812A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201791872A1 (ru) | Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение | |
EA201791019A1 (ru) | Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение | |
EA201591027A1 (ru) | Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение | |
EA201891103A1 (ru) | Композиции для лечения спинальной мышечной атрофии | |
EA202090486A3 (ru) | Соединения для лечения спинальной мышечной атрофии | |
EA201890200A1 (ru) | Производные циклизированного сульфамоилариламида и их применение в качестве лекарственных препаратов для лечения гепатита b | |
MX2017010506A (es) | Nuevo derivado de quinoleina para usarse en el tratamiento y prevencion de infecciones virales. | |
EA201790389A1 (ru) | Пирролопиримидиновые соединения, используемые в качестве агониста tlr7 | |
EA201591457A1 (ru) | Терапевтические соединения | |
EA201490647A1 (ru) | Производные бензотиазол-6-илуксусной кислоты и их применение для лечения вич-инфекции | |
NZ741957A (en) | Therapeutic compositions for treatment of human immunodeficiency virus | |
EA201990780A1 (ru) | Твердая форма соединения 4'-тио-2'-фторнуклеозид фосфамида и способ его получения и применения | |
EA202192268A1 (ru) | Мостиковые трициклические карбамоилпиридоновые соединения и их фармацевтическое применение | |
MX2019011173A (es) | Compuesto que contiene silicio para la resistencia a la infeccion por el virus de la hepatitis c. | |
EA201892732A1 (ru) | Противовирусные средства для лечения гепатита в | |
EA201892004A1 (ru) | Противовирусные средства для лечения гепатита b | |
UA111982C2 (uk) | Похідні бензотіазол-6-ілоцтової кислоти та їх застосування для лікування віл-інфекції |